About P&T JournalContacts:
Statement of Purpose
Guidelines for Authors
The authors conducted a retrospective study of failure rates and performed a cost-minimization analysis of azithromycin and clarithromycin.
Kavita Parmar-Lapasia, PharmD, Steven P. Gelone, PharmD, Michael R. Jacobs, PharmD, and Albert I. Wertheimer, PhD, MBA
Dr. Babinchak talks about the unexpected turns during his career in the field of infectious diseases.
Principles of Antibiotic Formulary Selection for P&T Committees, Part 5: The Cost of Antimicrobial Therapy
Dr. Cunha describes some of the cost factors that P&T committees should consider when selecting antibiotics.
Burke A. Cunha, MD
Dr. Micozzi provides an overview of the changes taking place in traditional medicine and the new roles of “alternative,” “complementary,” and “holistic” healing practices.
Marc S. Micozzi, MD, PhD
Dr. Goldenberg reviews bortezomib for injection (Velcade™) for multiple myeloma, gefitinib (Iressa™) for non-small cell lung cancer, and Bexxar® for non-Hodgkin’s lymphoma.
Marvin M. Goldenberg, PhD, RPh, MS
David Nash, MD, MBA, discusses the AMCP’s drug dossier format.
David B. Nash, MD, MBA
Stephen Barlas discusses Congressional efforts to create a Medicare discount drug card.
Matthew Grissinger explains the potential for errors with intravenous insulin infusions.
Matthew Grissinger, RPh, FASCP
P&T presents the latest information about approvals, indication changes, industry updates, and news from the FDA.
Drs. Ruffin and Harris review gefitinib (Iressa™), a new agent for the treatment of non-small cell lung cancer.
Charnelda G. Ruffin, PharmD, and Kathryn L. Harris, PharmD, MSHCM